Dermapharm Holding SE (FRA:DMP)

Germany flag Germany · Delayed Price · Currency is EUR
36.10
+0.40 (1.12%)
At close: Apr 8, 2025, 10:00 PM CET
10.91%
Market Cap 1.97B
Revenue (ttm) 1.20B
Net Income (ttm) 113.79M
Shares Out n/a
EPS (ttm) 2.11
PE Ratio 17.29
Forward PE n/a
Dividend 0.90 (2.49%)
Ex-Dividend Date Jun 27, 2025
Volume 30,956
Average Volume 50,557
Open 35.50
Previous Close 35.70
Day's Range 35.50 - 36.45
52-Week Range 30.15 - 42.50
Beta n/a
RSI 35.80
Earnings Date May 15, 2025

About Dermapharm Holding SE

Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany. The company operates through three segments: Branded Pharmaceuticals, Other Healthcare Products, and Parallel Import Business. It offers branded generics, OTC products, non-prescription healthcare products, and herbal extracts and parallel-imported originator pharmaceuticals. The company also provides vitamins, minerals, food supplements, as well as products for dermatology, allergology, pain and inflammation trea... [Read more]

Industry Pharmaceutical Preparations
Founded 1991
Employees 3,610
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol DMP
Full Company Profile

Financial Performance

In 2024, Dermapharm Holding SE's revenue was 1.20 billion, an increase of 3.89% compared to the previous year's 1.15 billion. Earnings were 113.79 million, an increase of 82.44%.

Financial Statements

News

Dermapharm's 2024: Revenue Soars, Surpassing EBITDA Expectations

Dermapharm's financial results for 2024 reflect a dynamic year of growth and strategic adjustments, setting a promising stage for the future. Jetzt den vollständigen Artikel lesen

14 days ago - Wallstreet:Online

EQS-News: Successful financial year 2024: Dermapharm increases revenue and exceeds EBITDA guidance

EQS-News: Dermapharm Holding SE / Key word(s): Annual Results/Annual Report Successful financial year 2024: Dermapharm increases revenue and exceeds EBITDA guidance 28.03.2025 / 07:30 CET/CEST The iss...

14 days ago - Wallstreet:Online

EQS-DD: Dermapharm Holding SE: Themis Beteiligungs-Aktiengesellschaft, buy

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 18.03.2025 / 13:12 CET/CEST The issuer is solely responsi...

24 days ago - Wallstreet:Online

Dermapharm Surpasses EBITDA Forecast with Revenue Boost

Dermapharm Holding SE's financial prowess shines with a 4% revenue boost, driven by 'Branded pharmaceuticals,' and a 10.2% EBITDA surge, setting the stage for promising growth in 2025. Jetzt den volls...

4 weeks ago - Wallstreet:Online

EQS-News: Dermapharm Holding SE increases revenue as projected and exceeds guidance for adjusted consolidated EBITDA

EQS-News: Dermapharm Holding SE / Key word(s): Annual Results/Preliminary Results Dermapharm Holding SE increases revenue as projected and exceeds guidance for adjusted consolidated EBITDA 14.03.2025 ...

4 weeks ago - Wallstreet:Online